Trials
Search / Trial NCT06441071

Patients' Positions on Analgesic Efficacy of ESPB

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Jun 2, 2024

Trial Information

Current as of February 19, 2025

Recruiting

Keywords

Paravertebral Thoracic Block Clinical Application Perioperative Analgesia Erector Spinae Plane Block

ClinConnect Summary

This clinical trial is investigating how the position patients stay in after receiving a specific type of pain relief called the erector spinae plane block (ESPB) affects their comfort after surgery. The main goal is to find out if lying on your stomach (prone) or side (lateral) for 30 minutes after receiving the block helps reduce pain more effectively compared to lying flat on your back (supine). Researchers will also compare how much pain medication patients need after surgery when using ESPB versus another method called paravertebral block (PVB).

To be eligible for this study, participants should be adults aged 18 to 80 who are having video-assisted thoracoscopic surgery, a type of minimally invasive chest surgery. They should have a body mass index (BMI) between 18 and 30, and be in generally good health. Throughout the trial, participants will be asked about their pain levels and overall recovery to help the researchers understand the best position for minimizing pain after surgery. If you are interested in participating, it’s important to know that some conditions, like allergies to the study medication or a history of opioid abuse, may prevent you from joining.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients undergoing Video-assisted Thoracoscopic Surgery under elective general anaesthesia were selected, regardless of sex, age 18-80 years, BMI: 18-30 kg.m-2, ASA classification I-III.
  • Exclusion Criteria:
  • 1. Allergy to the study drug or allergy to local anaesthetics;
  • 2. History of opioid abuse;
  • 3. Previous nerve block puncture with puncture site infection;
  • 4. Peripheral neuropathy;
  • 5. Coagulation abnormalities, defined as prothrombin time or partial activation time prothrombin time exceeding standard values or international normalised ratio (INR) ≥ 1.4, or platelet count ≤ 70 x 109 L-1.

Trial Officials

Tao Shan

Study Director

Nanjing First Hospital, Nanjing Medical University

About Nanjing First Hospital, Nanjing Medical University

Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.

Locations

Nanjing, Jiangsu, China

Nanjing, Jiangsu, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0